Search

Displaying results 1401 - 1410 of 9667 in total
  1. Drug

    Cariprazine

    go.drugbank.com/drugs/DB06016
    ApprovedInvestigational

    [A247100] It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. … Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary.

  2. Drug

    Enzacamene

    go.drugbank.com/drugs/DB11219
    Approved

    It is used in cosmetic products such as sunscreen to provide skin protection against UV rays. … Commonly known as 4-methylbenzylidene-camphor (4-MBC), enzacamene is a camphor derivative and an organic chemical UV-B filter.

    Mixtures: Secret Key Natural Cc Cushion Spf50 Pa / 02 Natural Cc, Qt Sun Block
  3. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    [A275507, A275508, A275511] It was identified through a targeted medicinal chemistry optimization campaign to act as a next-generation endocrine therapy for breast cancer. … [A275507, A275509] It serves as an advanced option to address the clinical challenge of endocrine-resistant breast cancer subtypes.

  4. Drug

    Isometheptene

    go.drugbank.com/drugs/DB06706
    Approved

    It is used for treating migraines and tension headaches.

    Mixtures: DIPIRONA SODICA / ISOMETEPTENO MUCATO/CAFEINA 300 MG / 30 MG/30MG TABLETA RECUBIERTA
  5. Drug

    Diatrizoate

    go.drugbank.com/drugs/DB00271
    ApprovedVet approved

    As diatrizoate meglumine and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.

    Mixtures: Peritrast 180mg Jod/ml - Lösung zur parenteralen Anwendung
  6. Drug

    Elacestrant

    go.drugbank.com/drugs/DB06374
    ApprovedInvestigational

    [A256838,L44918] In January 2023, it was approved by the FDA for the treatment of ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. … [L49334] Elacestrant binds to estrogen receptor-alpha (ERα) and acts as a selective estrogen receptor degrader (SERD) thanks to its ability to block the transcriptional activity of the ER and promote

  7. Drug

    Pralsetinib

    go.drugbank.com/drugs/DB15822
    ApprovedInvestigational

    [A202049, A202055, L15986] Although a phase 1/2 trial of pralsetinib termed ARROW (NCT03037385) is still ongoing, pralsetinib was granted accelerated FDA approval on September 4, 2020, for the treatment … of metastatic RET-fusion positive non-small cell lung cancer.

    Categories: Rearranged during Transfection (RET) Inhibitors
  8. Drug

    Acetarsol

    go.drugbank.com/drugs/DB13268
    ApprovedWithdrawn

    [L2622] It was first discovered in 1921 by Ernest Fourneau at the Pasteur Institute. It was developed by Neolab Inc, and approved by Health Canada as an antifungal on December 31, 1964. … It has been canceled and withdrawn from the market since August 12, 1997.[L1113]

  9. Drug

    Choline C-11

    go.drugbank.com/drugs/DB09563
    Approved

    Choline C 11 Injection is a radioactive diagnostic agent for positron emission tomography (PET) imaging of pat ients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized … tomography (CT) or magnetic resonance imaging.

  10. Drug

    Sodium acetate

    go.drugbank.com/drugs/DB09395
    ApprovedInvestigational

    Sodium acetate could be used as additives in food, industry, concrete manufacture, heating pads and in buffer solutions. … Medically, sodium acetate is important component as an electrolyte replenisher when given intravenously. It is mainly indicated to correct sodium levels in hyponatremic patients.

    Mixtures: Clinimix E, Clinimix E